Hepatitis C Information Central


Discover the latest news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information

News, Updates and Commentary

Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.

HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

77 more hepatitis cases may trace to clinic, officials say
LAS VEGAS --Seventy-seven more people who were treated at a Las Vegas outpatient clinic have been diagnosed with hepatitis C, health officials said. Authorities can't say for sure how the 77 people were infected, said Brian Labus, senior epidemiologist

77 more hepatitis cases may trace to clinic
LAS VEGAS (AP) - Health officials in Las Vegas say 77 more people who were treated at an outpatient clinic have been diagnosed with hepatitis C. Authorities can't say for sure how the 77 people were infected. Officials say they know each was treated from


UPDATES AND COMMENTARY RSS Feed

Highly Effective Against HCV Genotype 1
When tested on people with Hepatitis C genotype 1, R7128 proved to be an effective addition to combination therapy after just four weeks' time. In addition to its anti-viral effect, polymerase inhibitor R7128 received good marks for safety and minimal...

Investigational Drug Beats Standard Therapy in Hepatitis C Study
A Phase IIa trial investigating triple combination therapy with PEGASYS, COPEGUS and Roche's investigational drug R1626, demonstrated a higher response rate than traditional combination therapy alone. While R1626's effectiveness and high barrier to resistance makes it a top Hepatitis C...

Hepatitis C Complications Helped by Maintenance Interferon
A four-year study confirms that low-dosage maintenance interferon therapy prevents disease progression in those with portal hypertension or cirrhosis from Hepatitis C....

Zadaxin


SciClone's Goal...

SciClone's lead product, ZADAXIN thymosin alpha 1, is a 28 amino acid peptide. Originally isolated from the thymus gland, the drug is now produced through chemical synthesis. The effects of thymosin alpha 1 on the immune system have been studied extensively and are currently undergoing clinical evaluation in the treatment of chronic Hepatitis C and various other life- threatening diseases.

In various in vitro assays, ZADAXIN has been shown to stimulate the human immune system. It promotes the maturation of T-cells, which are involved in the control of various immune responses. As an immunomodulator, ZADAXIN represents a new class of therapy. Data suggest that ZADAXIN may be useful in a number of clinical conditions where alterations of the immune system may play a role in disease progression, such as Hepatitis C, non-small cell lung cancer and melanoma, and HIV/AIDS. ZADAXIN has been shown to be an extremely safe and well tolerated agent. There has been no evidence of toxicity and virtually no reports of drug-related side effects in over 2,000 patients studied to date.

SciClone recently completed its Hepatitis B clinical program with the completion of a Phase III clinical trial with ZADAXIN for chronic Hepatitis B in Taiwan. In the U.S. we are sponsoring a Phase III trial with ZADAXIN in combination therapy with alpha interferon to treat chronic Hepatitis C. In Japan, our licensee, Schering-Plough K.K., recently completed a Phase II clinical trial of ZADAXIN for chronic Hepatitis B. The drug is commercially approved in Singapore, the Philippines, and the People Õf Republic of China and registration has been filed for ZADAXIN in Hong Kong, India, Indonesia, and several other countries. In addition, SciClone anticipates filing approximately twelve additional ZADAXIN new drug applications for the treatment of chronic Hepatitis B in targeted markets prior to the end of 1996.

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 12 May 2008